GGrantIndex
← Leaderboards

Francesmary Modugno

University Of Pittsburgh At Pittsburgh

$3,651,054
Attributed
$3,651,054
Total exposure
13
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $774.2K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,651,054 · 13

By mechanism

R21$1,180,647 · 3
P50$1,112,424 · 2
K07$660,992 · 1
R03$371,917 · 3
M01$272,074 · 2
R13$53,000 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Neoplasm /Cancer Epidemiology

Research focus

Neoplasm /Cancer EpidemiologyClinical ResearchOvary NeoplasmsCancer RiskFemaleMalignant NeoplasmsWomanSpecimenBrca GeneBasic ScienceFundingMalignant Neoplasm Of OvaryBioinformaticsHuman TissueCancer Registry /ResourceImproved OutcomeEnvironmentBiometryHuman DataLeadershipCollaborationsCommunitiesBiological Specimen BanksClinic

Grant awards (30)

Multi-omics & AI-based imaging to identify biomarkers of molecular targets for breast cancer prevention$425,573
R21 · FY2025 · CA · contact PI
Core B: TCP: Translational Pathology Core$278,152
P50 · FY2025 · CA · contact PI
CEP: Career Enhancement Program$70,464
P50 · FY2025 · CA · contact PI
Core B: TCP: Translational Pathology Core$322,900
P50 · FY2024 · CA · contact PI
CEP: Career Enhancement Program$75,124
P50 · FY2024 · CA · contact PI
Core B: TCP: Translational Pathology Core$291,849
P50 · FY2023 · CA · contact PI
Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and Outcomes$146,330
R21 · FY2023 · CA · contact PI
CEP: Career Enhancement Program$73,935
P50 · FY2023 · CA · contact PI
Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and Outcomes$261,420
R21 · FY2022 · CA · contact PI
Ovarian Cancer: Prevention and Its Recurrence$13,000
R13 · FY2006 · CA · contact PI
HORMONE METABOLISM AND BREAST MASSES$99,930
M01 · FY2005 · RR
Planning Grant for a Study of the Effect of Radiation$74,250
R03 · FY2005 · CA
The Role of Prolactin in Postmenopausal Breast Cancer$74,250
R03 · FY2005 · CA
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERS$66,056
K07 · FY2005 · CA
NOVEL RISK FACTOR AND POTENTIAL EARLY DETECT MARK OVARIAN CANCER$50,298
M01 · FY2005 · RR
Ovarian Cancer: Prevention and Its Recurrence$5,000
R13 · FY2005 · CA
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERS$138,193
K07 · FY2004 · CA
Hormone Metabolism and Breast Masses$107,092
M01 · FY2004 · RR
The Role of Prolactin in Postmenopausal Breast Cancer$74,250
R03 · FY2004 · CA
Ovarian Cancer: Prevention and Its Recurrence$20,000
R13 · FY2004 · CA
Risk Factor &Potential Early Detection Mark Ovarian Ca$14,754
M01 · FY2004 · RR
Serum Markers of Breast /Ovarian Cancer Risk$172,761
R21 · FY2003 · CA
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERS$135,107
K07 · FY2003 · CA
Hormones, DNA Repair, BRCA1/2 and Ovarian Cancer Preven*$74,459
R03 · FY2003 · CA
Serum Markers of Breast /Ovarian Cancer Risk$174,563
R21 · FY2002 · CA
Hormones, DNA Repair, BRCA1/2 and Ovarian Cancer Preven*$74,708
R03 · FY2002 · CA
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERS$66,056
K07 · FY2002 · CA
Molecular/Biologic/Genetic Mechanisms of Ovarian Cancer$15,000
R13 · FY2002 · CA
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERS$129,202
K07 · FY2001 · CA
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERS$126,378
K07 · FY2000 · CA